Natasha Mithal

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Retreatment with radiotherapy for painful bone metastases

Natasha Mithal, Patricia R. Needham, Peter Hoskin · International Journal of Radiation Oncology*Biology*Physics · 1994 · 108 citations

Adaptive Radiotherapy, Painful Bone Metastases, Radiation Therapy +6

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

Galina Velikova, Linda Williams, Sarah Willis et al. · The Lancet Oncology · 2018 · 80 citations · Full text

Quality Of Life, Surgical Oncology, Radiation Therapy +11

DNA strand break rejoining defect in xrs-6 is complemented by transfection with the human Ku80 gene.

Gillian M. Ross, John J. Eady, Natasha Mithal et al. · PubMed · 1995 · 60 citations

Chromatin, Genome Instability, Ku Protein +15

A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol

Jonathan Shamash, Thomas Powles, Shah Jalal Sarker et al. · British Journal of Cancer · 2011 · 52 citations · Full text